Contact
searchSearch
HMP Global
Login

HER2-Low Breast Cancer Specialty Channel

Conference Coverage
HER2-Low Breast Cancer in the National Cancer Database
12/09/2022
Katie Herman
Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.
Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.
Daniel Peiffer, MD, PhD, and...
12/09/2022
Journal of Clinical Pathways
Conference Coverage
HER2-Positive Metastatic Breast Cancer Treatment Patterns in Patients Who Have Received at Least Two Lines of Therapy
12/07/2022
Katie Herman
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and...
12/07/2022
Journal of Clinical Pathways
Conference Coverage
Clinical and Pathological Differences in Breast Cancer Patients With HER2-low and Other Cancer Subtypes
12/07/2022
Katie Herman
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and...
12/07/2022
Journal of Clinical Pathways
Naoto Ueno, MD
Videos
Progression-Free Survival Associated With Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
10/20/2022
In an interview exploring the progression-free survival and overall survival among patients with HER2-low metastatic breast cancer who received one or two previous lines of chemotherapy, Naoto Ueno, MD, highlights the impacts that trastuzumab...
In an interview exploring the progression-free survival and overall survival among patients with HER2-low metastatic breast cancer who received one or two previous lines of chemotherapy, Naoto Ueno, MD, highlights the impacts that trastuzumab...
In an interview exploring the...
10/20/2022
Journal of Clinical Pathways
Sayeh Lavasani, MD, MS, FRCPC
Videos
Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment
10/16/2022
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC,...
10/16/2022
Journal of Clinical Pathways
News
State Legislative Trends in Biomarker Testing
09/20/2022
Yvette C. Terrie, BS Pharm, RPh
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
Sara Tolaney, MD, MPH
Videos
Factors Associated With a Greater Risk of Treatment Discontinuation in High-Risk Early Breast Cancer
08/03/2022
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses...
08/03/2022
Journal of Clinical Pathways
Shlomit Amar-Farkash, PhD, MSc
Videos
Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer
07/14/2022
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc,...
07/14/2022
Journal of Clinical Pathways
News
Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer
07/08/2022
Ellen Kurek
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways
Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network
Videos
Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer
07/06/2022
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA,...
07/06/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib
12/07/2021
Janelle Bradley
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients...
12/07/2021
Journal of Clinical Pathways

Expert Insights

Naoto Ueno, MD
Videos
Progression-Free Survival Associated With Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
10/20/2022
In an interview exploring the progression-free survival and overall survival among patients with HER2-low metastatic breast cancer who received one or two previous lines of chemotherapy, Naoto Ueno, MD, highlights the impacts that trastuzumab...
In an interview exploring the progression-free survival and overall survival among patients with HER2-low metastatic breast cancer who received one or two previous lines of chemotherapy, Naoto Ueno, MD, highlights the impacts that trastuzumab...
In an interview exploring the...
10/20/2022
Journal of Clinical Pathways
Sayeh Lavasani, MD, MS, FRCPC
Videos
Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment
10/16/2022
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC,...
10/16/2022
Journal of Clinical Pathways
Sara Tolaney, MD, MPH
Videos
Factors Associated With a Greater Risk of Treatment Discontinuation in High-Risk Early Breast Cancer
08/03/2022
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses...
08/03/2022
Journal of Clinical Pathways
Shlomit Amar-Farkash, PhD, MSc
Videos
Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer
07/14/2022
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc,...
07/14/2022
Journal of Clinical Pathways
Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network
Videos
Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer
07/06/2022
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA,...
07/06/2022
Journal of Clinical Pathways
Ethan Sokol, PhD
Videos
Real-World Outcomes of HR-Positive HER2-Negative Metastatic Breast Cancer Treated With ICIs
10/21/2021
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses...
10/21/2021
Journal of Clinical Pathways
Houda Hachad, PharmD
Interview
FDA Highlights Risks Associated With DPD Deficiency, Advises Testing Before Treatment
03/26/2025
Houda Hachad, PharmD
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US...
03/26/2025
Journal of Clinical Pathways
Upal Basu Roy, PhD, MPH
Interview
Project PRIORITY: Elevating the Patient Voice in EGFR-Positive NSCLC Care
03/24/2025
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu...
03/24/2025
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
03/24/2025
F. Randy Vogenberg, PhD, FASHP
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
03/24/2025
Journal of Clinical Pathways
Kohli Headshot
Interview
Strengthening Patient Pathways With BIS for Lymphedema Surveillance
03/24/2025
Manpreet Kohli, MD
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet...
03/24/2025
Journal of Clinical Pathways
Chelsea Renfro, PharmD
Interview
How Integrated Health System Pharmacies Enhance Treatment Adherence and Adverse Effect Management for CLL
03/21/2025
Houston Wyatt, PharmD; Chelsea E. Renfro, PharmD; Stephanie White, PharmD
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how...
03/21/2025
Journal of Clinical Pathways
Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
Graf Headshot
Interview
The Future of Chronic Lymphocytic Leukemia Management with Targeted Therapies
03/17/2025
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert...
03/17/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Advancing Value-Based Oncology With the Predictable Cost of Care Working Group: Part 2
03/17/2025
Gordon Kuntz; Carole Tremonti, RN, MBA
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology...
03/17/2025
Journal of Clinical Pathways
Brian S.
Interview
Key Advancements in Immunotherapy for Endometrial Cancer
03/13/2025
Brian M. Slomovitz, MD, MS
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses...
03/13/2025
Journal of Clinical Pathways
Brufsky Headshot
Interview
Transforming Metastatic Breast Cancer Care With AI and Real-World Evidence
03/11/2025
Adam Brufsky, MD, PhD
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky,...
03/11/2025
Journal of Clinical Pathways

Newsfeed

Conference Coverage
HER2-Low Breast Cancer in the National Cancer Database
12/09/2022
Katie Herman
Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.
Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.
Daniel Peiffer, MD, PhD, and...
12/09/2022
Journal of Clinical Pathways
Conference Coverage
HER2-Positive Metastatic Breast Cancer Treatment Patterns in Patients Who Have Received at Least Two Lines of Therapy
12/07/2022
Katie Herman
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and...
12/07/2022
Journal of Clinical Pathways
Conference Coverage
Clinical and Pathological Differences in Breast Cancer Patients With HER2-low and Other Cancer Subtypes
12/07/2022
Katie Herman
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and...
12/07/2022
Journal of Clinical Pathways
News
State Legislative Trends in Biomarker Testing
09/20/2022
Yvette C. Terrie, BS Pharm, RPh
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
News
Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer
07/08/2022
Ellen Kurek
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib
12/07/2021
Janelle Bradley
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Budget Impact of Blood-Based Biomarker Assay in Patients With Metastatic Breast Cancer
12/07/2021
Janelle Bradley
Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...
Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...
Use of a blood-based biomarker...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting
12/07/2021
Janelle Bradley
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases
12/06/2021
Janelle Bradley
Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.
Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.
Palbociclib plus letrozole is...
12/06/2021
Journal of Clinical Pathways
Conference Coverage
Recent Advancements in Biomarker Testing and Therapeutic Strategies in Oncology
05/03/2021
05/03/2021
Journal of Clinical Pathways
Conference Coverage
Delayed EGFR Testing in Early-Stage NSCLC Linked to Increased Health Care Utilization and Cost Burden
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
Study Explores Early Palliative Care Referral Patterns and Outcomes in SCLC
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
EHR-Embedded CDS Tool Enhances Specialty Drug Management in Oncology
03/28/2025
Juliet Gallagher
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented...
03/28/2025
Journal of Clinical Pathways
Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways
News
AI Revolutionizes Early Detection and Diagnosis of Gastric Cancer
03/14/2025
Lisa Kuhns, PhD, MD
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is...
03/14/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Early Measurable Residual Disease Assessment Predicts Survival in Patients With Mantle Cell Lymphoma
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use